Givaudan has acquired 25% of b.kolormakeup & skincare’s shares, an Italian company specialised in developing and producing make-up and skin care products.
Founded in 2000, b.kolor is headquartered close to Milan, Italy and employs around 250 employees. They are recognised experts in formulation design, focusing on innovation and sensory benefits allied to technical performance. They are engaged in all the phases of the creation process for make-up and skin care products, from pure ideation and its translation into a cosmetic formula, to the production of the final product. All-in-all, b.kolor is designing about 250 new products per year.
Reduce time to market
Thanks to this partnership, Givaudan is gaining access to production capacities for turnkey products. Givaudan aims to help their customers to accelerate their own development process to bring new products more quickly to the market. b.kolor will in return benefit from the access to Givaudan’s palette of ingredients, fragrances, and patented Fragrance & Beauty technologies.
“By sharing our creative and innovation capabilities, we will be able to generate additional value to our respective customers by providing a complete offer combining high levels of science, excellence in design and end-product manufacturing. This will benefit all our customers as they will gain speed to market with very innovative finished products,” said Maurizio Volpi, President Fragrance & Beauty at Givaudan.
“Givaudan’s capabilities in creation, ingredients and technology will greatly support us in evolving our product offering, while benefiting from Givaudan’s customer base and geographical footprint to expand ourselves in new territories. We are very pleased to also share our unique creative, design and production know-how with Givaudan to bring the products of tomorrow to the market,” added Maria-Teresa Sancini, Chairwoman of b.kolor.
Under the terms of the agreement, Givaudan has the option but not the obligation to acquire a controlling stake in b.kolor after a period of three years. The other terms of the deal have not be disclosed.
